Sources Contact Advanced Search Tutorials

An Interest In:

Web News this Week

Search Archive

Some of Our Sources

View All Sources

Help Webnuz

Referal links:

April 10, 2020 11:20 pm

NIH Begins Clinical Trial To Test Hydroxychloroquine To Treat COVID-19

The National Institutes of Health (NIH) announced Thursday that it's begun enrolling participants in a clinical trial to test the effectiveness of hydroxychloroquine in treating COVID-19. The Hill reports: The first participants have enrolled in the trial at Vanderbilt University Medical Center in Nashville, Tenn. The study will be conducted by the NIH's National Heart, Lung, and Blood Institute. According to the NIH, the blinded, placebo-controlled randomized clinical trial aims to enroll more than 500 adults who are currently hospitalized with COVID-19, the disease caused by the novel coronavirus, or who are in an emergency department with anticipated hospitalization. Participants will be randomly assigned to receive 400 mg of hydroxychloroquine twice daily for two doses (day one), then 200 mg twice daily for the subsequent eight doses (days two through five) or a placebo twice daily for five days. Hydroxychloroquine is used to treat malaria, lupus and rheumatoid conditions such as arthritis. However, its effectiveness at treating COVID-19 has never been proven, despite its embrace by President Trump. The evidence on hydroxychloroquine is conflicting, at best. NIH scientists said urgent clinical evidence is needed. Even so, the study is not estimated to be completed until July 2021.

Slashdot

Slashdot was originally created in September of 1997 by Rob "CmdrTaco" Malda. Today it is owned by Geeknet, Inc..

More About this Source Visit Slashdot